Lina Du

Lina Du

Auto-generated profile, based on publicly available information

Lina Du

Department of Chinese Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LDLi-Na Du
Li-Na Du
TXTong Xie
Tong Xie
JXJian-Ya Xu
Jian-Ya Xu
AKAn Kang
An Kang
LDLiu-Qing Di
Liu-Qing Di
SWShouchuan Wang
Shouchuan Wang

9 May 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZGZiyun Guo
Ziyun Guo
SLShaojing Li
Shaojing Li
CLChang Liu
Chang Liu
ZZZhongyi Zhu
Zhongyi Zhu
PWPanpan Wang
Panpan Wang
LDLina Du
Lina Du
Immunoglobulin A vasculitis (IgAV) is a systemic inflammatory disease that affects small blood vessels. Central nervous system (CNS) involvement in IgAV is rare. This study analyzed the clinical characteristics of IgAV patients combined with CNS damage in children. Furthermore, the study made a comparison between the characteristics of IgAV patients with and without CNS damage, and initially explored the potential predictors for IgAV patients with CNS damage. A retrospective analysis was conducted on a cohort of 50 children diagnosed with IgAV and admitted to Beijing Children’s Hospital from 2016 to 2019. The study encompassed a review of the clinical presentations, laboratory test results, imaging findings, therapeutic interventions, and prognoses of 10 children with IgAV who exhibited CNS involvement. These 10 cases were then compared with a group of 40 children with IgAV without CNS involvement. The prevalence of IgAV with CNS manifestations was 0.2%. The median age was 11.6 years, with a male-to-female ratio of 7:3. All CNS symptoms appeared after the purpuric rash. The mean period from IgAV onset to the development of neurological symptoms was 12.2 days (range: 1–27 days). Seizures were the most common neurological manifestation, with impaired consciousness and predominant convulsions. Other symptoms included headache, visual impairment, dysarthria, dyskinesia, and emotional irritation. The main abnormalities found on brain magnetic resonance imaging (MRI) were unilateral or bilateral abnormal focal signals, cortical and subcortical white matter edema, and thrombosis of the venous sinus. Glucocorticoid therapy and intravenous immunoglobulins were used to treat CNS damage caused by IgAV. All patients showed clinical improvement without recurrent neurological symptoms or sequelae. Statistically differences were identified in in terms of age, gastrointestinal damage, WBC count, NLR, ALB, C3 levels, and the CD4/CD8 ratio in IgAV patients with CNS damage when compared to those without CNS damage. Multivariable logistic regression analysis shows that age, NLR and C3 Levels are predictors of IgAV with CNS damage. CNS involvement in IgAV is a rare complication. Its clinical manifestations are diverse and vary in severity, and its diagnosis is exclusionary. Brain MRI is beneficial for diagnosis and follow-up. Steroid therapy is important for treating IgAV-associated CNS involvement. Age, NLR and C3 Levels are predictors of IgAV with CNS damage.

5 October 2022 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LDLina Du
Lina Du
CLChang Liu
Chang Liu
XWXintai Wang
Xintai Wang
JMJing Mu
Jing Mu
YYYan Yang
Yan Yang